Newer products lead Sanofi-Aventis to growth in Japan
This article was originally published in Scrip
Sanofi-Aventis still sees good potential for the growth of its business in Japan, driven in large part by new launches and line extensions for core cardiovascular products.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.